{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:06:33Z","timestamp":1793318793614,"version":"4.5.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:00:00Z","timestamp":1626134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The pharmacological interventions available for individuals in the early stages of psychosis are extremely limited. For those at clinical high risk for psychosis, there is no licensed treatment available. For those with first-episode psychosis, all licensed antipsychotic medications act via dopamine D\n                    <jats:sub>2<\/jats:sub>\n                    receptors. While treatment with antipsychotics is transformative in some patients, in others, it is ineffective. In addition, these medications can often cause adverse effects which make patients reluctant to take them. This is a particular problem in the early phases of psychosis, when patients are being treated for the first time, as unpleasant experiences may colour their future attitude towards treatment. Recent research has suggested that cannabidiol (CBD), a compound found in the\n                    <jats:italic>Cannabis sativa<\/jats:italic>\n                    plant, may have antipsychotic effects and relatively few adverse effects and could therefore be an ideal treatment for the early phases of psychosis, when minimising adverse effects is a clinical priority. In this review, we consider CBD\u2019s potential as a treatment in the clinical high risk and first-episode stages of psychosis. First, we describe the limitations of existing treatments at these two stages. We then describe what is known of CBD\u2019s mechanisms of action, effectiveness as a treatment for psychosis, adverse effects and acceptability to patients. We discuss how some of the outstanding issues about the utility of CBD in the early phases of psychosis may be resolved through ongoing clinical trials. Finally, we consider the impact of recreational cannabis use and over-the-counter cannabinoids preparations and discuss the potential therapeutic role of other compounds that modulate the endocannabinoid system in psychosis.\n                  <\/jats:p>","DOI":"10.1007\/s00213-021-05905-9","type":"journal-article","created":{"date-parts":[[2021,7,13]],"date-time":"2021-07-13T00:03:03Z","timestamp":1626134583000},"page":"1179-1190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Cannabidiol (CBD) as a novel treatment in the early phases of psychosis"],"prefix":"10.1007","volume":"239","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2851-5252","authenticated-orcid":false,"given":"Edward","family":"Chesney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,13]]},"reference":[{"key":"5905_CR1","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00213-019-05442-6","volume":"237","author":"E Appiah-Kusi","year":"2020","unstructured":"Appiah-Kusi E, Petros N, Wilson R et al (2020) Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis. Psychopharmacology 237:1121\u20131130. https:\/\/doi.org\/10.1007\/s00213-019-05442-6","journal-title":"Psychopharmacology"},{"key":"5905_CR2","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/npp.2009.184","volume":"35","author":"S Bhattacharyya","year":"2010","unstructured":"Bhattacharyya S, Morrison PD, Fusar-Poli P et al (2010) Opposite effects of \u03b4-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology 35:764\u2013774. https:\/\/doi.org\/10.1038\/npp.2009.184","journal-title":"Neuropsychopharmacology"},{"key":"5905_CR3","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1001\/archgenpsychiatry.2011.161","volume":"69","author":"S Bhattacharyya","year":"2012","unstructured":"Bhattacharyya S, Crippa JA, Allen P et al (2012) Induction of psychosis by \u03949-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Arch Gen Psychiatry 69:27\u201336. https:\/\/doi.org\/10.1001\/archgenpsychiatry.2011.161","journal-title":"Arch Gen Psychiatry"},{"key":"5905_CR4","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1093\/schbul\/sby014.067","volume":"44","author":"S Bhattacharyya","year":"2018","unstructured":"Bhattacharyya S, Wilson R, Allen P et al (2018a) 17.3 Effect of cannabidiol on symptoms, distress and neurophysiological abnormalities in clinical high-risk for psychosis patients: a placebo-controlled study. Schizophr Bull 44:S28\u2013S28. https:\/\/doi.org\/10.1093\/schbul\/sby014.067","journal-title":"Schizophr Bull"},{"key":"5905_CR5","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1001\/jamapsychiatry.2018.2309","volume":"75","author":"S Bhattacharyya","year":"2018","unstructured":"Bhattacharyya S, Wilson R, Appiah-Kusi E et al (2018b) Effect of cannabidiol on medial temporal, midbrain, and striatal dysfunction in people at clinical high risk of psychosis: a randomized clinical trial. JAMA Psychiat 75:1107\u20131117. https:\/\/doi.org\/10.1001\/jamapsychiatry.2018.2309","journal-title":"JAMA Psychiat"},{"key":"5905_CR6","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1080\/09638237.2017.1294735","volume":"26","author":"J Bjornestad","year":"2017","unstructured":"Bjornestad J, Davidson L, Joa I et al (2017) Antipsychotic treatment: experiences of fully recovered service users. J Ment Heal 26:264\u2013270. https:\/\/doi.org\/10.1080\/09638237.2017.1294735","journal-title":"J Ment Heal"},{"key":"5905_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.schres.2011.11.009","volume":"134","author":"DL Boggs","year":"2012","unstructured":"Boggs DL, Kelly DL, McMahon RP et al (2012) Rimonabant for neurocognition in schizophrenia: a 16-week double blind randomized placebo controlled trial. Schizophr Res 134:207\u2013210. https:\/\/doi.org\/10.1016\/j.schres.2011.11.009","journal-title":"Schizophr Res"},{"key":"5905_CR8","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1007\/s00213-018-4885-9","volume":"235","author":"DL Boggs","year":"2018","unstructured":"Boggs DL, Surti T, Gupta A et al (2018) The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial. Psychopharmacology 235:1923\u20131932. https:\/\/doi.org\/10.1007\/s00213-018-4885-9","journal-title":"Psychopharmacology"},{"key":"5905_CR9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.bpsc.2020.06.018","volume":"6","author":"F Borgan","year":"2021","unstructured":"Borgan F, Kokkinou M, Howes O (2021) The cannabinoid CB1 receptor in schizophrenia. Biol Psychiatry Cogn Neurosci Neuroimaging 6:646\u2013659. https:\/\/doi.org\/10.1016\/j.bpsc.2020.06.018","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"5905_CR10","doi-asserted-by":"publisher","first-page":"S200","DOI":"10.1093\/schbul\/sbz021.271","volume":"45","author":"M Bossong","year":"2019","unstructured":"Bossong M, Wilson R, Appiah-Kusi E et al (2019) O12.7. Treatment with cannabidiol reduces resting state perfusion in individuals at clinical high risk for psychosis. Schizophr Bull 45:S200\u2013S200. https:\/\/doi.org\/10.1093\/schbul\/sbz021.271","journal-title":"Schizophr Bull"},{"key":"5905_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.schres.2009.09.019","volume":"115","author":"H Boter","year":"2009","unstructured":"Boter H, Peuskens J, Libiger J et al (2009) Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res 115:97\u2013103. https:\/\/doi.org\/10.1016\/j.schres.2009.09.019","journal-title":"Schizophr Res"},{"key":"5905_CR12","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/jcm8070989","volume":"8","author":"J Brown","year":"2019","unstructured":"Brown J, Winterstein A (2019) Potential adverse drug events and drug\u2013drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med 8:989. https:\/\/doi.org\/10.3390\/jcm8070989","journal-title":"J Clin Med"},{"key":"5905_CR13","doi-asserted-by":"publisher","unstructured":"Chesney E, McGuire P, Freeman TP et al (2020a) Lack of evidence for the effectiveness or safety of over-the-counter cannabidiol products. Ther Adv Psychopharmacol 10. https:\/\/doi.org\/10.1177\/2045125320954992","DOI":"10.1177\/2045125320954992"},{"key":"5905_CR14","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41386-020-0667-2","volume":"45","author":"E Chesney","year":"2020","unstructured":"Chesney E, Oliver D, Green A et al (2020b) Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology 45:1799\u20131806. https:\/\/doi.org\/10.1038\/s41386-020-0667-2","journal-title":"Neuropsychopharmacology"},{"key":"5905_CR15","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","volume":"370","author":"R Christensen","year":"2007","unstructured":"Christensen R, Kristensen PK, Bartels EM et al (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706\u20131713. https:\/\/doi.org\/10.1016\/S0140-6736(07)61721-8","journal-title":"Lancet"},{"key":"5905_CR16","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.3389\/fpsyt.2020.587154","volume":"11","author":"IL Cortez","year":"2020","unstructured":"Cortez IL, Rodrigues da Silva N, Guimar\u00e3es FS, Gomes FV (2020) Are CB2 receptors a new target for schizophrenia treatment? Front Psychiatry 11:1137. https:\/\/doi.org\/10.3389\/fpsyt.2020.587154","journal-title":"Front Psychiatry"},{"key":"5905_CR17","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/wps.20526","volume":"17","author":"C Davies","year":"2018","unstructured":"Davies C, Cipriani A, Ioannidis JPA et al (2018a) Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis. World Psychiatry 17:196\u2013209. https:\/\/doi.org\/10.1002\/wps.20526","journal-title":"World Psychiatry"},{"key":"5905_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3389\/fpsyt.2018.00187","volume":"9","author":"C Davies","year":"2018","unstructured":"Davies C, Radua J, Cipriani A et al (2018b) Efficacy and acceptability of interventions for attenuated positive psychotic symptoms in individuals at clinical high risk of psychosis: a network meta-analysis. Front Psychiatry 9:187. https:\/\/doi.org\/10.3389\/fpsyt.2018.00187","journal-title":"Front Psychiatry"},{"key":"5905_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-020-0862-2","volume":"10","author":"C Davies","year":"2020","unstructured":"Davies C, Wilson R, Appiah-Kusi E et al (2020) A single dose of cannabidiol modulates medial temporal and striatal function during fear processing in people at clinical high risk for psychosis. Transl Psychiatry 10:1\u201312. https:\/\/doi.org\/10.1038\/s41398-020-0862-2","journal-title":"Transl Psychiatry"},{"key":"5905_CR20","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S2215-0366(18)30427-9","volume":"6","author":"DC D\u2019Souza","year":"2019","unstructured":"D\u2019Souza DC, Cortes-Briones J, Creatura G et al (2019) Efficacy and safety of a fatty acid amide hydrolase inhibitor (PF-04457845) in the treatment of cannabis withdrawal and dependence in men: a double-blind, placebo-controlled, parallel group, phase 2a single-site randomised controlled trial. Lancet Psychiatry 6:35\u201345. https:\/\/doi.org\/10.1016\/S2215-0366(18)30427-9","journal-title":"Lancet Psychiatry"},{"key":"5905_CR21","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1089\/cap.2018.0040","volume":"28","author":"JB Edgcomb","year":"2018","unstructured":"Edgcomb JB, Zima B (2018) Medication adherence among children and adolescents with severe mental illness: a systematic review and meta-analysis. J Child Adolesc Psychopharmacol 28:508\u2013520. https:\/\/doi.org\/10.1089\/cap.2018.0040","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"5905_CR22","doi-asserted-by":"publisher","first-page":"8711","DOI":"10.1074\/jbc.M114.618447","volume":"290","author":"MW Elmes","year":"2015","unstructured":"Elmes MW, Kaczocha M, Berger WT et al (2015) Fatty acid-binding proteins (FABPs) are intracellular carriers for \u03949-tetrahydrocannabinol (THC) and cannabidiol (CBD). J Biol Chem 290:8711\u20138721. https:\/\/doi.org\/10.1074\/jbc.M114.618447","journal-title":"J Biol Chem"},{"key":"5905_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1177\/0269881112460109","volume":"27","author":"A Englund","year":"2013","unstructured":"Englund A, Morrison PD, Nottage J et al (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol 27:19\u201327. https:\/\/doi.org\/10.1177\/0269881112460109","journal-title":"J Psychopharmacol"},{"key":"5905_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1177\/0269881115615104","volume":"30","author":"A Englund","year":"2016","unstructured":"Englund A, Atakan Z, Kralj A et al (2016) The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: a placebo-controlled, double-blind, crossover pilot trial. J Psychopharmacol 30:140\u2013151. https:\/\/doi.org\/10.1177\/0269881115615104","journal-title":"J Psychopharmacol"},{"key":"5905_CR25","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s00127-019-01810-x","volume":"55","author":"MS Farris","year":"2020","unstructured":"Farris MS, Shakeel MK, Addington J (2020) Cannabis use in individuals at clinical high-risk for psychosis: a comprehensive review. Soc Psychiatry Psychiatr Epidemiol 55:527\u2013537. https:\/\/doi.org\/10.1007\/s00127-019-01810-x","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"5905_CR26","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.tips.2011.08.005","volume":"32","author":"CS Ferguson","year":"2011","unstructured":"Ferguson CS, Tyndale RF (2011) Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends Pharmacol Sci 32:708\u2013714. https:\/\/doi.org\/10.1016\/j.tips.2011.08.005","journal-title":"Trends Pharmacol Sci"},{"key":"5905_CR27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/2045125316672136","volume":"7","author":"JS Frankel","year":"2017","unstructured":"Frankel JS, Schwartz TL (2017) Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol 7:29\u201341. https:\/\/doi.org\/10.1177\/2045125316672136","journal-title":"Ther Adv Psychopharmacol"},{"key":"5905_CR28","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1016\/S2215-0366(20)30290-X","volume":"7","author":"TP Freeman","year":"2020","unstructured":"Freeman TP, Hindocha C, Baio G et al (2020) Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial. Lancet Psychiatry 7:865\u2013874. https:\/\/doi.org\/10.1016\/S2215-0366(20)30290-X","journal-title":"Lancet Psychiatry"},{"key":"5905_CR29","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1001\/jamapsychiatry.2019.4779","volume":"77","author":"P Fusar-Poli","year":"2020","unstructured":"Fusar-Poli P, Salazar De Pablo G, Correll CU et al (2020) Prevention of psychosis: advances in detection, prognosis, and intervention. JAMA Psychiat 77:755\u2013765. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.4779","journal-title":"JAMA Psychiat"},{"key":"5905_CR30","volume-title":"CBD in the UK","author":"B Gibbs","year":"2019","unstructured":"Gibbs B, Yates DA, Liebling J (2019) CBD in the UK. Centre for Medicinal Cannabis, London"},{"key":"5905_CR31","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/bcp.14028","volume":"86","author":"GJ Groeneveld","year":"2020","unstructured":"Groeneveld GJ, Martin JH (2020) Parasitic pharmacology: a plausible mechanism of action for cannabidiol. Br J Clin Pharmacol 86:189\u2013191. https:\/\/doi.org\/10.1111\/bcp.14028","journal-title":"Br J Clin Pharmacol"},{"key":"5905_CR32","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eurpsy.2013.03.002","volume":"29","author":"KP Hayhurst","year":"2014","unstructured":"Hayhurst KP, Drake RJ, Massie JA et al (2014) Improved quality of life over one year is associated with improved adherence in patients with schizophrenia. Eur Psychiatry 29:191\u2013196. https:\/\/doi.org\/10.1016\/j.eurpsy.2013.03.002","journal-title":"Eur Psychiatry"},{"key":"5905_CR33","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.psychres.2018.04.002","volume":"264","author":"LM Hickling","year":"2018","unstructured":"Hickling LM, Kouvaras S, Nterian Z, Perez-Iglesias R (2018) Non-adherence to antipsychotic medication in first-episode psychosis patients. Psychiatry Res 264:151\u2013154. https:\/\/doi.org\/10.1016\/j.psychres.2018.04.002","journal-title":"Psychiatry Res"},{"key":"5905_CR34","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.euroneuro.2018.10.004","volume":"28","author":"M Hobbs","year":"2018","unstructured":"Hobbs M, Kalk NJ, Morrison PD, Stone JM (2018) Spicing it up-synthetic cannabinoid receptor agonists and psychosis\u2014a systematic review. Eur Neuropsychopharmacol 28:1289\u20131304. https:\/\/doi.org\/10.1016\/j.euroneuro.2018.10.004","journal-title":"Eur Neuropsychopharmacol"},{"key":"5905_CR35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1192\/bjp.bp.111.105833","volume":"201","author":"OD Howes","year":"2012","unstructured":"Howes OD, Vergunst F, Gee S et al (2012) Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry 201:481\u2013485. https:\/\/doi.org\/10.1192\/bjp.bp.111.105833","journal-title":"Br J Psychiatry"},{"key":"5905_CR36","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn M, Nikolakopoulou A, Schneider-Thoma J et al (2019) Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394:939\u2013951. https:\/\/doi.org\/10.1016\/S0140-6736(19)31135-3","journal-title":"Lancet"},{"key":"5905_CR37","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","volume":"191","author":"GE Hunt","year":"2018","unstructured":"Hunt GE, Large MM, Cleary M et al (2018) Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990\u20132017: systematic review and meta-analysis. Drug Alcohol Depend 191:234\u2013258. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.07.011","journal-title":"Drug Alcohol Depend"},{"key":"5905_CR38","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S0010-440X(95)90068-3","volume":"36","author":"HJ Jackson","year":"1995","unstructured":"Jackson HJ, McGorry PD, Dudgeon P (1995) Prodromal symptoms of schizophrenia in first-episode psychosis: prevalence and specificity. Compr Psychiatry 36:241\u2013250. https:\/\/doi.org\/10.1016\/S0010-440X(95)90068-3","journal-title":"Compr Psychiatry"},{"key":"5905_CR39","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.euroneuro.2018.12.014","volume":"29","author":"MR Jacobson","year":"2019","unstructured":"Jacobson MR, Watts JJ, Boileau I et al (2019) A systematic review of phytocannabinoid exposure on the endocannabinoid system: implications for psychosis. Eur Neuropsychopharmacol 29:330\u2013348. https:\/\/doi.org\/10.1016\/j.euroneuro.2018.12.014","journal-title":"Eur Neuropsychopharmacol"},{"key":"5905_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2019.107704","volume":"172","author":"SJ Kaar","year":"2020","unstructured":"Kaar SJ, Natesan S, McCutcheon R, Howes OD (2020) Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology. Neuropharmacology 172:107704. https:\/\/doi.org\/10.1016\/j.neuropharm.2019.107704","journal-title":"Neuropharmacology"},{"key":"5905_CR41","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S2215-0366(18)30252-9","volume":"5","author":"RS Kahn","year":"2018","unstructured":"Kahn RS, Winter van Rossum I, Leucht S et al (2018) Amisulpride and olanzapine followed by open-label treatment with clozapine in first-episode schizophrenia and schizophreniform disorder (OPTiMiSE): a three-phase switching study. Lancet Psychiatry 5:797\u2013807. https:\/\/doi.org\/10.1016\/S2215-0366(18)30252-9","journal-title":"Lancet Psychiatry"},{"key":"5905_CR42","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","volume":"64","author":"RSE Keefe","year":"2007","unstructured":"Keefe RSE, Bilder RM, Davis SM et al (2007) Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64:633\u2013647. https:\/\/doi.org\/10.1001\/archpsyc.64.6.633","journal-title":"Arch Gen Psychiatry"},{"key":"5905_CR43","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1017\/S0033291718001393","volume":"49","author":"T Kishi","year":"2019","unstructured":"Kishi T, Ikuta T, Matsui Y et al (2019) Effect of discontinuation v. maintenance of antipsychotic medication on relapse rates in patients with remitted\/stable first-episode psychosis: a meta-analysis. Psychol Med 49:772\u2013779. https:\/\/doi.org\/10.1017\/S0033291718001393","journal-title":"Psychol Med"},{"key":"5905_CR44","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1056\/nejmoa1911772","volume":"382","author":"KS Koblan","year":"2020","unstructured":"Koblan KS, Kent J, Hopkins SC et al (2020) A non\u2013D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med 382:1497\u20131506. https:\/\/doi.org\/10.1056\/nejmoa1911772","journal-title":"N Engl J Med"},{"key":"5905_CR45","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1017\/S0033291715002329","volume":"46","author":"T Kraan","year":"2016","unstructured":"Kraan T, Velthorst E, Koenders L et al (2016) Cannabis use and transition to psychosis in individuals at ultra-high risk: review and meta-analysis. Psychol Med 46:673\u2013681. https:\/\/doi.org\/10.1017\/S0033291715002329","journal-title":"Psychol Med"},{"key":"5905_CR46","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00406-018-0869-3","volume":"268","author":"M Krause","year":"2018","unstructured":"Krause M, Zhu Y, Huhn M et al (2018) Antipsychotic drugs for patients with schizophrenia and predominant or prominent negative symptoms: a systematic review and meta-analysis. Eur Arch Psychiatry Clin Neurosci 268:625\u2013639. https:\/\/doi.org\/10.1007\/s00406-018-0869-3","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"5905_CR47","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.eurpsy.2004.06.031","volume":"19","author":"M Lambert","year":"2004","unstructured":"Lambert M, Conus P, Eide P et al (2004) Impact of present and past antipsychotic side effects on attitude toward typical antipsychotic treatment and adherence. Eur Psychiatry 19:415\u2013422. https:\/\/doi.org\/10.1016\/j.eurpsy.2004.06.031","journal-title":"Eur Psychiatry"},{"key":"5905_CR48","doi-asserted-by":"publisher","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, Bagher AM, Kelly MEM, Denovan-Wright EM (2015) Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol 172:4790\u20134805. https:\/\/doi.org\/10.1111\/bph.13250","journal-title":"Br J Pharmacol"},{"key":"5905_CR49","doi-asserted-by":"publisher","first-page":"e94","DOI":"10.1038\/tp.2012.15","volume":"2","author":"FM Leweke","year":"2012","unstructured":"Leweke FM, Piomelli D, Pahlisch F et al (2012) Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry 2:e94\u2013e94. https:\/\/doi.org\/10.1038\/tp.2012.15","journal-title":"Transl Psychiatry"},{"key":"5905_CR50","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/s0920-9964(14)70153-7","volume":"153","author":"FM Leweke","year":"2014","unstructured":"Leweke FM, Hellmich M, Pahlisch F et al (2014) Modulation of the endocannabinoid system as a potential new target in the treatment of schizophrenia. Schizophr Res 153:S47. https:\/\/doi.org\/10.1016\/s0920-9964(14)70153-7","journal-title":"Schizophr Res"},{"key":"5905_CR51","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40263-013-0046-1","volume":"27","author":"CC Liu","year":"2013","unstructured":"Liu CC, Demjaha A (2013) Antipsychotic interventions in prodromal psychosis: safety issues. CNS Drugs 27:197\u2013205. https:\/\/doi.org\/10.1007\/s40263-013-0046-1","journal-title":"CNS Drugs"},{"key":"5905_CR52","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/nchembio.129","volume":"5","author":"JZ Long","year":"2009","unstructured":"Long JZ, Li W, Booker L et al (2009) Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol 5:37\u201344. https:\/\/doi.org\/10.1038\/nchembio.129","journal-title":"Nat Chem Biol"},{"key":"5905_CR53","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1177\/0004867418815982","volume":"53","author":"C Makiol","year":"2019","unstructured":"Makiol C, Kluge M (2019) Remission of severe, treatment-resistant schizophrenia following adjunctive cannabidiol. Aust N Z J Psychiatry 53:262. https:\/\/doi.org\/10.1177\/0004867418815982","journal-title":"Aust N Z J Psychiatry"},{"key":"5905_CR54","doi-asserted-by":"publisher","first-page":"498","DOI":"10.5414\/CP202687","volume":"54","author":"C Mallet","year":"2016","unstructured":"Mallet C, Dubray C, Dual\u00e9 C (2016) FAAH inhibitors in the limelight, but regrettably. Int J Clin Pharmacol Ther 54:498\u2013501. https:\/\/doi.org\/10.5414\/CP202687","journal-title":"Int J Clin Pharmacol Ther"},{"key":"5905_CR55","doi-asserted-by":"publisher","first-page":"744","DOI":"10.3389\/fphar.2017.00744","volume":"8","author":"E Mart\u00ednez-Pinilla","year":"2017","unstructured":"Mart\u00ednez-Pinilla E, Varani K, Reyes-Resina I et al (2017) Binding and signaling studies disclose a potential allosteric site for cannabidiol in cannabinoid CB2 receptors. Front Pharmacol 8:744. https:\/\/doi.org\/10.3389\/fphar.2017.00744","journal-title":"Front Pharmacol"},{"key":"5905_CR56","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.4088\/JCP.08r04472","volume":"70","author":"PD McGorry","year":"2009","unstructured":"McGorry PD, Nelson B, Amminger GP et al (2009) Intervention in individuals at ultra-high risk for psychosis: a review and future directions. J Clin Psychiatry 70:1206\u20131212. https:\/\/doi.org\/10.4088\/JCP.08r04472","journal-title":"J Clin Psychiatry"},{"key":"5905_CR57","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1176\/appi.ajp.2017.17030325","volume":"175","author":"P McGuire","year":"2018","unstructured":"McGuire P, Robson P, Cubala WJ et al (2018) Cannabidiol (CBD) as an adjunctive therapy in schizophrenia: a multicenter randomized controlled trial. Am J Psychiatry 175:225\u2013231. https:\/\/doi.org\/10.1176\/appi.ajp.2017.17030325","journal-title":"Am J Psychiatry"},{"key":"5905_CR58","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/bph.12944","volume":"172","author":"JM McPartland","year":"2015","unstructured":"McPartland JM, Duncan M, Di Marzo V, Pertwee RG (2015) Are cannabidiol and \u03949-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review. Br J Pharmacol 172:737\u2013753. https:\/\/doi.org\/10.1111\/bph.12944","journal-title":"Br J Pharmacol"},{"key":"5905_CR59","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1176\/appi.ajp.161.6.975","volume":"161","author":"HY Meltzer","year":"2004","unstructured":"Meltzer HY, Arvanitis L, Bauer D, Rein W (2004) Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am J Psychiatry 161:975\u2013984. https:\/\/doi.org\/10.1176\/appi.ajp.161.6.975","journal-title":"Am J Psychiatry"},{"key":"5905_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s42238-021-00061-5","volume":"3","author":"J Moltke","year":"2021","unstructured":"Moltke J, Hindocha C (2021) Reasons for cannabidiol use: a cross-sectional study of CBD users, focusing on self-perceived stress, anxiety, and sleep problems. J Cannabis Res 3:1\u201312. https:\/\/doi.org\/10.1186\/s42238-021-00061-5","journal-title":"J Cannabis Res"},{"key":"5905_CR61","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/978-3-319-45541-9_4","volume":"103","author":"P Morales","year":"2017","unstructured":"Morales P, Hurst DP, Reggio PH (2017) Molecular targets of the phytocannabinoids: a complex picture. Prog Chem Org Nat Prod 103:103\u2013131. https:\/\/doi.org\/10.1007\/978-3-319-45541-9_4","journal-title":"Prog Chem Org Nat Prod"},{"key":"5905_CR62","volume-title":"The Maudsley guidelines on advanced prescribing in psychosis","author":"P Morrison","year":"2019","unstructured":"Morrison P, Taylor DM, Mcguire P (2019) The Maudsley guidelines on advanced prescribing in psychosis. John Wiley & Sons"},{"key":"5905_CR63","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fmolb.2020.00144","volume":"7","author":"C Muller","year":"2020","unstructured":"Muller C, Lynch DL, Hurst DP, Reggio PH (2020) A closer look at anandamide interaction with TRPV1. Front Mol Biosci 7:144. https:\/\/doi.org\/10.3389\/fmolb.2020.00144","journal-title":"Front Mol Biosci"},{"key":"5905_CR64","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.psychres.2009.05.004","volume":"176","author":"D Novick","year":"2010","unstructured":"Novick D, Haro JM, Suarez D et al (2010) Predictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 176:109\u2013113. https:\/\/doi.org\/10.1016\/j.psychres.2009.05.004","journal-title":"Psychiatry Res"},{"key":"5905_CR65","doi-asserted-by":"publisher","unstructured":"O\u2019Neill A, Wilson R, Blest-Hopley G et al (2020) Normalization of mediotemporal and prefrontal activity, and mediotemporal-striatal connectivity, may underlie antipsychotic effects of cannabidiol in psychosis. Psychol Med 1\u201311. https:\/\/doi.org\/10.1017\/S0033291719003519","DOI":"10.1017\/S0033291719003519"},{"key":"5905_CR66","doi-asserted-by":"publisher","unstructured":"O\u2019Neill A, Annibale L, Blest-Hopley G et al (2021) Cannabidiol modulation of hippocampal glutamate in early psychosis. J Psychopharmacol 02698811211001107. https:\/\/doi.org\/10.1177\/02698811211001107","DOI":"10.1177\/02698811211001107"},{"key":"5905_CR67","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1093\/schbul\/sbz039","volume":"46","author":"D Oliver","year":"2020","unstructured":"Oliver D, Reilly TJ, Baccaredda Boy O et al (2020) What causes the onset of psychosis in individuals at clinical high risk? A meta-analysis of risk and protective factors. Schizophr Bull 46:110\u2013120. https:\/\/doi.org\/10.1093\/schbul\/sbz039","journal-title":"Schizophr Bull"},{"key":"5905_CR68","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.schres.2016.10.014","volume":"181","author":"JL Padmanabhan","year":"2017","unstructured":"Padmanabhan JL, Shah JL, Tandon N, Keshavan MS (2017) The \u201cpolyenviromic risk score\u201d: aggregating environmental risk factors predicts conversion to psychosis in familial high-risk subjects. Schizophr Res 181:17\u201322. https:\/\/doi.org\/10.1016\/j.schres.2016.10.014","journal-title":"Schizophr Res"},{"key":"5905_CR69","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/sj.bjp.0707442","volume":"153","author":"RG Pertwee","year":"2008","unstructured":"Pertwee RG (2008) The diverse CB 1 and CB 2 receptor pharmacology of three plant cannabinoids: \u0394 9-tetrahydrocannabinol, cannabidiol and \u0394 9-tetrahydrocannabivarin. Br J Pharmacol 153:199\u2013215. https:\/\/doi.org\/10.1038\/sj.bjp.0707442","journal-title":"Br J Pharmacol"},{"key":"5905_CR70","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1037\/a0030992","volume":"28","author":"SM Robinson","year":"2014","unstructured":"Robinson SM, Sobell LC, Sobell MB, Leo GI (2014) Reliability of the Timeline Followback for cocaine, cannabis, and cigarette use. Psychol Addict Behav 28:154\u2013162. https:\/\/doi.org\/10.1037\/a0030992","journal-title":"Psychol Addict Behav"},{"key":"5905_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.104749","volume":"156","author":"N Rodrigues da Silva","year":"2020","unstructured":"Rodrigues da Silva N, Gomes FV, Sonego AB et al (2020) Cannabidiol attenuates behavioral changes in a rodent model of schizophrenia through 5-HT1A, but not CB1 and CB2 receptors. Pharmacol Res 156:104749. https:\/\/doi.org\/10.1016\/j.phrs.2020.104749","journal-title":"Pharmacol Res"},{"key":"5905_CR72","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1038\/sj.bjp.0707460","volume":"152","author":"E Ryberg","year":"2007","unstructured":"Ryberg E, Larsson N, Sj\u00f6gren S et al (2007) The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol 152:1092\u20131101. https:\/\/doi.org\/10.1038\/sj.bjp.0707460","journal-title":"Br J Pharmacol"},{"key":"5905_CR73","unstructured":"Sanofi-Aventis (2009) Efficacy and safety of AVE1625 as a co-treatment with antipsychotic therapy in schizophrenia (CONNECT). In: ClinicalTrials.gov. http:\/\/clinicaltrials.gov\/show\/NCT00439634. Accessed 1 Nov 2020"},{"key":"5905_CR74","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.eurpsy.2015.01.013","volume":"30","author":"SJ Schmidt","year":"2015","unstructured":"Schmidt SJ, Schultze-Lutter F, Schimmelmann BG et al (2015) EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry 30:388\u2013404. https:\/\/doi.org\/10.1016\/j.eurpsy.2015.01.013","journal-title":"Eur Psychiatry"},{"key":"5905_CR75","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.yebeh.2018.07.027","volume":"88","author":"KA Schoedel","year":"2018","unstructured":"Schoedel KA, Szeto I, Setnik B et al (2018) Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: a randomized, double-blind, controlled trial. Epilepsy Behav 88:162\u2013171. https:\/\/doi.org\/10.1016\/j.yebeh.2018.07.027","journal-title":"Epilepsy Behav"},{"key":"5905_CR76","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S2215-0366(15)00363-6","volume":"3","author":"T Schoeler","year":"2016","unstructured":"Schoeler T, Monk A, Sami MB et al (2016) Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. Lancet Psychiatry 3:215\u2013225. https:\/\/doi.org\/10.1016\/S2215-0366(15)00363-6","journal-title":"Lancet Psychiatry"},{"key":"5905_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2016.195","volume":"6","author":"P Seeman","year":"2016","unstructured":"Seeman P (2016) Cannabidiol is a partial agonist at dopamine D2 high receptors, predicting its antipsychotic clinical dose. Transl Psychiatry 6:e920. https:\/\/doi.org\/10.1038\/tp.2016.195","journal-title":"Transl Psychiatry"},{"key":"5905_CR78","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.psychres.2014.11.002","volume":"225","author":"KV Sendt","year":"2015","unstructured":"Sendt KV, Tracy DK, Bhattacharyya S (2015) A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Res 225:14\u201330. https:\/\/doi.org\/10.1016\/j.psychres.2014.11.002","journal-title":"Psychiatry Res"},{"key":"5905_CR79","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1192\/bjp.bp.115177261","volume":"209","author":"D Siskind","year":"2016","unstructured":"Siskind D, McCartney L, Goldschlager R, Kisely S (2016) Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. Br J Psychiatry 209:385\u2013392. https:\/\/doi.org\/10.1192\/bjp.bp.115177261","journal-title":"Br J Psychiatry"},{"key":"5905_CR80","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0117166","volume":"10","author":"MR Stafford","year":"2015","unstructured":"Stafford MR, Mayo-Wilson E, Loucas CE et al (2015) Efficacy and safety of pharmacological and psychological interventions for the treatment of psychosis and schizophrenia in children, adolescents and young adults: a systematic review and meta-analysis. PLoS ONE 10:e0117166. https:\/\/doi.org\/10.1371\/journal.pone.0117166","journal-title":"PLoS ONE"},{"key":"5905_CR81","volume-title":"The Maudsley prescribing guidelines in psychiatry\u2013eleventh edition","author":"DM Taylor","year":"2018","unstructured":"Taylor DM, Barnes TRE, Young AH (2018) The Maudsley prescribing guidelines in psychiatry\u2013eleventh edition. John Wiley & Sons"},{"key":"5905_CR82","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/j.biopsych.2005.08.019","volume":"59","author":"ET Tzavara","year":"2006","unstructured":"Tzavara ET, Li DL, Moutsimilli L et al (2006) Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol Psychiatry 59:508\u2013515. https:\/\/doi.org\/10.1016\/j.biopsych.2005.08.019","journal-title":"Biol Psychiatry"},{"key":"5905_CR83","doi-asserted-by":"publisher","first-page":"2503","DOI":"10.1017\/S0033291714000117","volume":"44","author":"LR Valmaggia","year":"2014","unstructured":"Valmaggia LR, Day FL, Jones C et al (2014) Cannabis use and transition to psychosis in people at ultra-high risk. Psychol Med 44:2503\u20132512. https:\/\/doi.org\/10.1017\/S0033291714000117","journal-title":"Psychol Med"},{"key":"5905_CR84","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.cpr.2016.10.009","volume":"51","author":"M Wade","year":"2017","unstructured":"Wade M, Tai S, Awenat Y, Haddock G (2017) A systematic review of service-user reasons for adherence and nonadherence to neuroleptic medication in psychosis. Clin Psychol Rev 51:75\u201395. https:\/\/doi.org\/10.1016\/j.cpr.2016.10.009","journal-title":"Clin Psychol Rev"},{"key":"5905_CR85","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/j.biopsych.2020.03.003","volume":"88","author":"JJ Watts","year":"2020","unstructured":"Watts JJ, Jacobson MR, Lalang N et al (2020) Imaging brain fatty acid amide hydrolase in untreated patients with psychosis. Biol Psychiatry 88:727\u2013735. https:\/\/doi.org\/10.1016\/j.biopsych.2020.03.003","journal-title":"Biol Psychiatry"},{"key":"5905_CR86","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1111\/eip.12077","volume":"8","author":"P Welsh","year":"2014","unstructured":"Welsh P, Tiffin PA (2014) Assessing adolescent preference in the treatment of first-episode psychosis and psychosis risk. Early Interv Psychiatry 8:281\u2013285. https:\/\/doi.org\/10.1111\/eip.12077","journal-title":"Early Interv Psychiatry"},{"key":"5905_CR87","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1159\/000479554","volume":"23","author":"S Welter","year":"2017","unstructured":"Welter S, L\u00fccke C, Lam AP et al (2017) Synthetic cannabinoid use in a psychiatric patient population: a pilot study. Eur Addict Res 23:182\u2013193. https:\/\/doi.org\/10.1159\/000479554","journal-title":"Eur Addict Res"},{"key":"5905_CR88","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41398-019-0534-2","volume":"9","author":"R Wilson","year":"2019","unstructured":"Wilson R, Bossong MG, Appiah-Kusi E et al (2019) Cannabidiol attenuates insular dysfunction during motivational salience processing in subjects at clinical high risk for psychosis. Transl Psychiatry 9:1\u201310. https:\/\/doi.org\/10.1038\/s41398-019-0534-2","journal-title":"Transl Psychiatry"},{"key":"5905_CR89","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1038\/npp.2011.17","volume":"36","author":"TT Winton-Brown","year":"2011","unstructured":"Winton-Brown TT, Allen P, Bhattacharrya S et al (2011) Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an fMRI study. Neuropsychopharmacology 36:1340\u20131348. https:\/\/doi.org\/10.1038\/npp.2011.17","journal-title":"Neuropsychopharmacology"},{"key":"5905_CR90","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k2827","volume":"361","author":"J Wise","year":"2018","unstructured":"Wise J (2018) FDA approves its first cannabis based medicine. BMJ 361:k2827. https:\/\/doi.org\/10.1136\/bmj.k2827","journal-title":"BMJ"},{"key":"5905_CR91","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.apnu.2015.05.006","volume":"29","author":"E Y\u0131lmaz","year":"2015","unstructured":"Y\u0131lmaz E, Okanl\u0131 A (2015) The effect of internalized stigma on the adherence to treatment in patients with schizophrenia. Arch Psychiatr Nurs 29:297\u2013301. https:\/\/doi.org\/10.1016\/j.apnu.2015.05.006","journal-title":"Arch Psychiatr Nurs"},{"key":"5905_CR92","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/0269881114562090","volume":"29","author":"SL Young","year":"2015","unstructured":"Young SL, Taylor M, Lawrie SM (2015) \u201cFirst do no harm\u201d. A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol 29:353\u2013362. https:\/\/doi.org\/10.1177\/0269881114562090","journal-title":"J Psychopharmacol"},{"key":"5905_CR93","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.prostaglandins.2014.11.002","volume":"116\u2013117","author":"S Zelasko","year":"2015","unstructured":"Zelasko S, Arnold WR, Das A (2015) Endocannabinoid metabolism by cytochrome P450 monooxygenases. Prostaglandins Other Lipid Mediat 116\u2013117:112\u2013123. https:\/\/doi.org\/10.1016\/j.prostaglandins.2014.11.002","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"5905_CR94","doi-asserted-by":"publisher","first-page":"E5007","DOI":"10.1073\/pnas.1413210111","volume":"111","author":"HY Zhang","year":"2014","unstructured":"Zhang HY, Gao M, Liu QR et al (2014) Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci 111:E5007\u2013E5015. https:\/\/doi.org\/10.1073\/pnas.1413210111","journal-title":"Proc Natl Acad Sci"},{"key":"5905_CR95","first-page":"485","volume":"56","author":"AW Zuardi","year":"1995","unstructured":"Zuardi AW, Morais SL, Guimaraes FS, Mechoulam R (1995) Antipsychotic effect of cannabidiol. J Clin Psychiatry 56:485\u2013486","journal-title":"J Clin Psychiatry"},{"key":"5905_CR96","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1177\/0269881106060967","volume":"20","author":"AW Zuardi","year":"2006","unstructured":"Zuardi AW, Hallak JEC, Dursun SM et al (2006) Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 20:683\u2013686. https:\/\/doi.org\/10.1177\/0269881106060967","journal-title":"J Psychopharmacol"},{"key":"5905_CR97","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1177\/0269881108096519","volume":"23","author":"AW Zuardi","year":"2009","unstructured":"Zuardi AW, Crippa JAS, Hallak JEC et al (2009) Cannabidiol for the treatment of psychosis in Parkinsons disease. J Psychopharmacol 23:979\u2013983. https:\/\/doi.org\/10.1177\/0269881108096519","journal-title":"J Psychopharmacol"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05905-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00213-021-05905-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-021-05905-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T01:06:14Z","timestamp":1652663174000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00213-021-05905-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,13]]},"references-count":97,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["5905"],"URL":"https:\/\/doi.org\/10.1007\/s00213-021-05905-9","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,13]]},"assertion":[{"value":"6 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}